People · Operator
Named in public records as an officer, director or promoter · active 2009–2024 · Biotechnology, Biotech / Pharma, Other Technology, Other, Retailing
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Fulcrum Therapeutics, Inc. | — | Biotechnology | Series C | $183.2M | $2.8B | 2016 |
| Sherlock Biosciences, Inc. | — | Biotech / Pharma | Series C | $112.8M | $1.7B | 2019 |
| Senti Biosciences, Inc. | — | Biotechnology | Series B | $77.0M | $222.0M | 2024 |
| Saf-T-Pay, Inc | — | Other Technology | Series B | $24.8M | $569.2M | 2009 |
| Photo Holdings, Inc. | — | Other | Seed | $3.0M | $55.8M | 2011 |
| Awakn Life Sciences Corp. | — | Other | Seed | $2.6M | $3.6M | 2022 |
| Awakn Life Sciences Inc. | — | Other | Seed | $1.6M | $21.5M | 2021 |
| Golocker Enterprises, Inc. | — | Retailing | Seed | $1.1M | $4.5M | 2022 |
James Collins at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside James Collins on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| George Scorsis | 2 | 6 |
| Jonathan Held | 2 | 4 |
| Benjamin Sessa | 2 | 2 |
| Anthony Tennyson | 2 | 2 |
| Oren Zeev | 1 | 12 |
| Edward Mathers | 1 | 12 |
| Ed Mathers | 1 | 11 |
| Mark Levin | 1 | 9 |
| Michael Rubin | 1 | 8 |
| Alex Kolicich | 1 | 8 |
| Simon Anderson | 1 | 7 |
| David Walt | 1 | 6 |
| James Tananbaum | 1 | 6 |
| Paul Carter | 1 | 4 |
| Jason Kiefer | 1 | 4 |
| Philip Lee | 1 | 4 |
| Alan Ezekowitz | 1 | 4 |
| Robert Gould | 1 | 3 |
| James Geraghty | 1 | 3 |
| Steve Page | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.